Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders
Pharming Group (EURONEXT: PHARM/Nasdaq: PHAR) announced that shareholders approved all proposals at their Extraordinary General Meeting (EGM). Fabrice Chouraqui has been appointed as Executive Director and Chief Executive Officer for a four-year term, effective immediately. He succeeds Sijmen de Vries, who will remain as a strategic advisor until December 31, 2025, to ensure a smooth transition.
Shareholders also approved specific components of Chouraqui's remuneration package. The company has made available a recording of the webcast and presentation slides from the EGM on their website's Investor Relations section.
Pharming Group (EURONEXT: PHARM/Nasdaq: PHAR) ha annunciato che gli azionisti hanno approvato tutte le proposte durante l'Assemblea Generale Straordinaria (EGM). Fabrice Chouraqui è stato nominato Direttore Esecutivo e Amministratore Delegato per un mandato di quattro anni, con effetto immediato. Succede a Sijmen de Vries, che rimarrà come consulente strategico fino al 31 dicembre 2025, per garantire una transizione agevole.
Gli azionisti hanno anche approvato specifici componenti del pacchetto retributivo di Chouraqui. L'azienda ha reso disponibile una registrazione del webcast e delle diapositive della presentazione dell'EGM nella sezione Relazioni con gli Investitori del loro sito web.
Pharming Group (EURONEXT: PHARM/Nasdaq: PHAR) anunció que los accionistas aprobaron todas las propuestas en su Junta General Extraordinaria (EGM). Fabrice Chouraqui ha sido nombrado Director Ejecutivo y Consejero Delegado por un período de cuatro años, con efecto inmediato. Sucede a Sijmen de Vries, quien permanecerá como asesor estratégico hasta el 31 de diciembre de 2025, para asegurar una transición fluida.
Los accionistas también aprobaron componentes específicos del paquete de remuneración de Chouraqui. La empresa ha puesto a disposición una grabación de la transmisión en vivo y las diapositivas de la presentación de la EGM en la sección de Relaciones con Inversores de su sitio web.
Pharming Group (EURONEXT: PHARM/Nasdaq: PHAR)는 주주들이 특별총회(EGM)에서 모든 제안을 승인했다고 발표했습니다. Fabrice Chouraqui가 즉시 발효되는 4년 임기의 전무이사 및 CEO로 임명되었습니다. 그는 Sijmen de Vries의 뒤를 이어, de Vries는 2025년 12월 31일까지 전략 고문으로 남아 원활한 전환을 보장할 것입니다.
주주들은 또한 Chouraqui의 보상 패키지의 특정 구성 요소를 승인했습니다. 회사는 EGM의 웹캐스트 및 발표 슬라이드 녹화를 투자자 관계 섹션의 웹사이트에 제공했습니다.
Pharming Group (EURONEXT: PHARM/Nasdaq: PHAR) a annoncé que les actionnaires ont approuvé toutes les propositions lors de leur Assemblée Générale Extraordinaire (AGE). Fabrice Chouraqui a été nommé Directeur Exécutif et Président-Directeur Général pour un mandat de quatre ans, prenant effet immédiatement. Il succède à Sijmen de Vries, qui restera conseiller stratégique jusqu'au 31 décembre 2025, afin d'assurer une transition en douceur.
Les actionnaires ont également approuvé des éléments spécifiques du package de rémunération de Chouraqui. L'entreprise a mis à disposition un enregistrement du webinaire et des diapositives de présentation de l'AGE dans la section Relations Investisseurs de son site web.
Pharming Group (EURONEXT: PHARM/Nasdaq: PHAR) gab bekannt, dass die Aktionäre auf ihrer außerordentlichen Hauptversammlung (EGM) alle Vorschläge genehmigt haben. Fabrice Chouraqui wurde mit sofortiger Wirkung für eine vierjährige Amtszeit als Geschäftsführer und CEO ernannt. Er folgt Sijmen de Vries nach, der bis zum 31. Dezember 2025 als strategischer Berater bleiben wird, um einen reibungslosen Übergang zu gewährleisten.
Die Aktionäre genehmigten auch spezifische Komponenten des Vergütungspakets von Chouraqui. Das Unternehmen hat eine Aufzeichnung des Webcasts und der Präsentationsfolien von der EGM im Bereich Investor Relations ihrer Website zur Verfügung gestellt.
- Smooth leadership transition with former CEO staying as advisor through 2025
- All EGM proposals approved by shareholders
- None.
Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda.
Shareholders approved the appointment of Mr. Fabrice Chouraqui as Executive Director and Chief Executive Officer for a term of four years.
As a result, Mr. Chouraqui succeeds Mr. Sijmen de Vries with immediate effect. To ensure a smooth hand-over of tasks and responsibilities, Mr. de Vries will remain a strategic advisor to the new CEO until December 31, 2025.
In addition, shareholders also approved the proposal to approve certain components of the remuneration package of Mr. Chouraqui in his capacity as Executive Director and Chief Executive Officer.
A recording of the webcast, presentation slides from today’s EGM, and more details regarding both agenda items are available on the Pharming website in the Investor Relations section.
Dr. Richard Peters, Chairman of the Board of Directors, commented:
“On behalf of the entire Board, we welcome Fabrice Chouraqui as our new Executive Director and Chief Executive Officer and we look forward to working with him to deliver on Pharming’s objectives and to further strengthen the company’s position in the rare disease market. We would also like to thank our outgoing Chief Executive Officer, Sijmen de Vries, for his significant accomplishments and leadership over the past 16 years and for remaining as strategic advisor through year end.”
About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.
For more information, visit www.pharming.com and find us on LinkedIn.
Inside Information
This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
For further public information, contact:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com
FTI Consulting, London, UK
Simon Conway/Alex Shaw/Amy Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
Attachment
FAQ
Who is the new CEO of Pharming Group (PHARM) as of March 2025?
How long will former Pharming Group (PHARM) CEO Sijmen de Vries stay as advisor?
What was approved at Pharming Group's (PHARM) March 2025 EGM?
What is the duration of Fabrice Chouraqui's appointment as PHARM's CEO?
